Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

FGFR

The fibroblast growth factor receptors (FGFR) are, as their name implies, receptors that bind to members of the fibroblast growth factor (FGF) family of proteins. Some of these receptors are involved in pathological conditions. For example, a point mutation in FGFR3 can lead to achondroplasia.

Lenvatinib
E7080
T0520417716-92-8
Lenvatinib (E7080) is a multi-target receptor tyrosine kinase inhibitor that inhibits VEGFR1-3, FGFR1-4, KIT, PDGFR, and RET, and has oral activity. Lenvatinib has the strongest inhibitory activity on VEGFR2 and VEGFR3 (IC50=4/5.2 nM). Lenvatinib has strong anti-tumor activity.
  • $40
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Nintedanib
Intedanib, BIBF 1120
T1777656247-17-5
Nintedanib (Intedanib) is a triple vascular kinase inhibitor that inhibits VEGFR1, VEGFR2, and VEGFR3 (IC50=34/13/13 nM), FGFR1, FGFR2, and FGFR3 (IC50=69/37/108 nM), PDGFRα, and PDGFRβ (IC50=59/65 nM). Nintedanib has antitumor activity and inhibits tumor growth by inhibiting angiogenesis.
  • $38
In Stock
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Heparan Sulfate
T193559050-30-0
Heparan sulfate is a natural product, a linear polysaccharide. Heparan sulfate occurs as a proteoglycan (HSPG) that is tightly attached to cell surface or extracellular matrix proteins.
  • $44
In Stock
Size
QTY
TargetMol | Citations Cited
TYRA-300
TYRA-300-B01, TYRA300
T888412800223-30-5
TYRA-300 is an oral and selective FGFR3 inhibitor with an IC50 value of 11 nM and 25-fold, 14-fold, and 36-fold selectivity for FGFR1, FGFR2, and FGFR4, respectively, in the Ba/F3 cell line for the treatment of metastatic uroepithelial carcinomas (mUCs) and chondrodysplasia.
  • $392
In Stock
Size
QTY
Pemigatinib
INCB054828
T124011513857-77-6
Pemigatinib (INCB054828) is an orally active, selective inhibitor of FGFR, with IC50 values of 0.4 nM for FGFR1, 0.5 nM for FGFR2, 1.2 nM for FGFR3, and 30 nM for FGFR4.
  • $41
In Stock
Size
QTY
TargetMol | Citations Cited
Nintedanib esylate
Nintedanib Ethanesulfonate Salt, BIBF 1120 (esylate)
T5001656247-18-6
Nintedanib esylate (BIBF 1120 esylate) is a potent triple angiokinase inhibitor targeting VEGFR1/2/3, FGFR1/2/3, and PDGFRα/β.
  • $30
In Stock
Size
QTY
Regorafenib
Fluoro-Sorafenib, BAY 73-4506
T1792755037-03-7
Regorafenib (BAY 73-4506) is an orally active, multi-targeted receptor tyrosine kinase inhibitor that inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ, exhibiting both antitumor and anti-angiogenic activity.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
Ponatinib
AP24534
T2372943319-70-8
Ponatinib (AP24534) is an orally available, multitargeted kinase inhibitor with IC50 values of 0.37 nM (Abl), 1.1 nM (PDGFRα), 1.5 nM (VEGFR2), 2.2 nM (FGFR1), and 5.4 nM (Src).
  • $35
In Stock
Size
QTY
TargetMol | Citations Cited
Infigratinib
NVP-BGJ398, BGJ-398
T1975872511-34-7
Infigratinib (NVP-BGJ398) (BGJ398) is an orally bioavailable pan FGFR inhibitor (IC50: 0.9/1.4/1 nM for FGFR1/2/3), >40-fold selective for FGFR versus FGFR4 and VEGFR2.
  • $39
In Stock
Size
QTY
TargetMol | Citations Cited
CEP-11981
T68539856691-93-5
CEP-11981 is an orally active TIE2/pan-VEGFR inhibitor with broad tyrosine kinase inhibitory activity, exhibiting antitumour and anti-angiogenic effects, and is applicable for the treatment of refractory solid tumours.
  • $275
In Stock
Size
QTY
Erdafitinib
JNJ-42756493
T37261346242-81-6
Erdafitinib (JNJ-42756493), a quinoxaline derivative, targets FGFR1/2/3/4.
  • $39
In Stock
Size
QTY
TargetMol | Citations Cited
Gunagratinib
ICP-192, ICP192
T396822211082-53-8
Gunagratinib (ICP-192) is an orally active and highly effective pan-FGFR (fibroblast growth factor receptor) inhibitor, used in studies of FGFR-related diseases.
  • $66
In Stock
Size
QTY
Sulfatinib
KDR-IN-1
T40751308672-74-3
Sulfatinib (KDR-IN-1) (HMPL-012) is a potent and highly selective tyrosine kinase inhibitor against VEGFR1/2/3, FGFR1 and CSF1R with IC 50 s ranging from 1 to 24 nM.
  • $39
In Stock
Size
QTY
Resigratinib
KIN-3248, KIN3248
T798562750709-91-0
Resigratinib (KIN-3248) is a FGFR tyrosine kinase inhibitor exhibiting antineoplastic activity [1].
  • $81
In Stock
Size
QTY
Irpagratinib
ABSK011, ABSK 011
T798502230974-62-4
Irpagratinib (ABSK011) is an orally active and highly effective FGFR4 antagonist with antitumor activity, inhibiting FGFR4 autophosphorylation and blocking FGFR4 signaling to downstream pathways. It is used in studies of gastrointestinal diseases and cancer.
  • $92
In Stock
Size
QTY
Fisogatinib
BLU-554, BLU554, BLU 554
T34561707289-21-1
Fisogatinib (BLU-554) is a highly potent, selective and orally active FGFR4 inhibitor with an IC50 value of 5 nM and significant anti-tumor activity in hepatocellular carcinoma models dependent on FGFR4 signaling.
  • $48
In Stock
Size
QTY
TargetMol | Citations Cited
Aprutumab
FGFR-moAb, FGFR2-TTC, BAY 1179470
T766721634620-63-5
Aprutumab (BAY 1179470) is a human FGFR2 monoclonal antibody with affinity to FGFR2 isoforms FGFR2-IIIB and FGFR2-IIIC. Aprutumab is commonly used to synthesize antibody-drug conjugates.
  • $479
In Stock
Size
QTY
Danusertib
PHA-739358
T2094827318-97-8
Danusertib (PHA-739358) is a small-molecule 3-aminopyrazole derivative with potential antineoplastic activity. Danusertib binds to and inhibits the Aurora kinases, which may result in cell growth arrest and apoptosis in tumor cells in which Aurora kinases are overexpressed.
  • $48
In Stock
Size
QTY
TargetMol | Citations Cited
Ferulic Acid
Fumalic Acid, Coniferic acid
T22151135-24-6
Ferulic Acid (Coniferic acid) is a highly abundant phenolic phytochemical and a type of organic compound found in the Ferula assafoetida L. or Ligusticum chuanxiong.It can be absorbed by the small intestine and excreted through the urine.
  • $30
In Stock
Size
QTY
TargetMol | Citations Cited
Lenvatinib mesylate
E7080 (mesylate)
T8541857890-39-2
Lenvatinib mesylate (E7080 (mesylate)) is an oral and multi-targeted inhibitor of VEGFR1-3, FGFR1-4, PDGFR, KIT, and RET, with potent antitumor activities.
  • $34
In Stock
Size
QTY
TargetMol | Citations Cited
Fazpilodemab
RO7040551, RO 7040551, RG7992, RG 7992, BFKB-8488A, BFKB8488A
T774202517935-02-1
Fazpilodemab (BFKB8488A) is a fully humanized bispecific antibody selectively targeting and activating the Klotho β and fibroblast growth factor receptor 1c receptor complex, which can be used to study non-alcoholic fatty liver disease (NAFLD).
  • $447
In Stock
Size
QTY
Formononetin
Formononetol, Flavosil, Biochanin B
T0724485-72-3
Formononetin (Flavosil) is an O-methylated isoflavone and a phytoestrogen from the root of Astragalus membranaceus.
  • $45
In Stock
Size
QTY
TargetMol | Citations Cited
Pazopanib
GW786034
T0097L444731-52-6
Pazopanib (GW786034) is an inhibitor of protein tyrosine kinases that inhibits VEGFR1, VEGFR2, VEGFR3, PDGFRβ, c-Kit, FGFR1, and c-Fms (IC50=10/30/47/84/74/140/146 nM). Pazopanib has antitumor activity.
  • $42
In Stock
Size
QTY
TargetMol | Citations Cited
Futibatinib
TAS120, FGFR-IN-1
T50441448169-71-8
Futibatinib (TAS-120) is an orally active, potent, selective, highly bioavailable, and irreversible FGFR inhibitor with IC50 values ​​of 3.9, 1.3, 1.6, and 8.3 nM for FGFR1, FGFR2, FGFR3, and FGFR4, respectively. [2]
  • $48
In Stock
Size
QTY